

1 **Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal**  
2 **swabs versus saliva samples in COVID-19 hospitalized patients: results of a**  
3 **prospective comparative trial (RESTART).**

4

5 Antonios Kritikos<sup>1\*</sup>, Giorgia Caruana<sup>1\*</sup>, René Brouillet<sup>1</sup>, John-Paul Miroz<sup>2</sup>, Abed-Maillard  
6 Samia<sup>2</sup>, Stieger Geraldine<sup>2</sup>, Onya Opota<sup>1</sup>, Antony Croxatto<sup>1</sup>, Peter Vollenweider<sup>3</sup>, Pierre-  
7 Alexandre Bart<sup>3</sup>, Jean-Daniel Chiche<sup>2</sup>, Gilbert Greub<sup>1</sup>

8

9 <sup>1</sup> Institute of Microbiology, Lausanne University Hospital and University of Lausanne

10 <sup>2</sup> Intensive Care Unit, Lausanne University Hospital and University of Lausanne

11 <sup>3</sup> Service of Internal Medicine, Lausanne University Hospital and University of Lausanne

12

13 \*Equal contribution.

14

15 **Corresponding Author**

16 Prof. Gilbert Greub

17 Institute of Microbiology, Department of Laboratory Medicine, Lausanne University Hospital  
18 and University of Lausanne

19 Rue du Bugnon 48, CH-1011, Lausanne, Switzerland

20 E-mail : [gilbert.greub@chuv.ch](mailto:gilbert.greub@chuv.ch)

21 Tel.: +41 (0)21 314 49 79. Personal: +41 (0)79 556 17 95

22 Fax: +41 (0)21 314 40 60

23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Word Count**

25 **Abstract: 256 words**

26 **Main text: 2749 words**

27

28 **Running title: Evaluation of salivary RT-PCR and rapid antigen testing in COVID-19**

29 **hospitalized patients.**

30

31 **Keywords:** SARS-CoV-2 diagnosis, RT-PCR, rapid antigen testing, saliva, viral transport medium

32

33 **Abbreviations:**

34 NP: Nasopharyngeal

35 RT-PCR: Real time polymerase chain reaction

36 POCT: Rapid Point-of-Care Test

37 RAT: Rapid Antigen Test

38 VTM: Viral Transport Medium

39 ICU: Intensive Care Unit

40 FOPH: Federal Office of Public Health

41 VL: Viral Load

42 Ct: Cycle threshold

43 IQR: Interquartile range

44

45

46

47

48 **Abstract**

49

50 **Objectives:** Saliva sampling could serve as an alternative non-invasive sample for SARS-CoV-  
51 2 diagnosis while rapid antigen testing (RAT) might help to mitigate the shortage of reagents  
52 sporadically encountered with RT-PCR. Thus, in the RESTART study we compared antigen  
53 and RT-PCR testing methods on nasopharyngeal (NP) swabs and salivary samples.

54 **Methods:** We conducted a prospective observational study among COVID-19 hospitalized  
55 patients between 10<sup>th</sup> December 2020 and 1<sup>st</sup> February 2021. Paired saliva and NP samples  
56 were investigated by RT-PCR (Cobas 6800, Roche-Switzerland) and by two rapid antigen  
57 tests: One Step Immunoassay Exdia<sup>®</sup> COVID-19 Ag (Precision Biosensor, Korea) and Standard  
58 Q<sup>®</sup> COVID-19 Rapid Antigen Test (Roche-Switzerland).

59 **Results:** A total of 58 paired NP-saliva specimens were collected. Thirty-two of 58 (55%)  
60 patients were hospitalized in the intensive care unit and the median duration of symptoms  
61 was 11 days (IQR 5-19). NP and salivary RT-PCR exhibited sensitivity of 98% and 69%  
62 respectively whereas the specificity of these RT-PCRs assays were of 100%. NP RAT exhibited  
63 much lower diagnostic performances with sensitivities of 35% and 41% for the Standard Q<sup>®</sup>  
64 and Exdia<sup>®</sup> assays respectively, when a wet-swab approach was used (i.e. when the swab was  
65 diluted in the viral transport medium (VTM) before testing). The sensitivity of the dry-swab  
66 approach was slightly better (47%). These antigen tests exhibited very low sensitivity (4 and  
67 8%) when applied to salivary swabs.

68 **Conclusions:** Nasopharyngeal RT-PCR is the most accurate test for COVID-19 diagnosis in  
69 hospitalized patients. RT-PCR on salivary samples may be used when nasopharyngeal swabs  
70 are contraindicated. RAT are not appropriate for hospitalized patients.

71

## 72 **Introduction**

73

74 Rapid and accurate detection of SARS-CoV-2 infection in hospitalized patients is the  
75 cornerstone of prompt patient care and contact tracing. To date, nasopharyngeal (NP) swab  
76 real-time polymerase chain reaction (RT-PCR) remains the reference specimen for SARS-CoV-  
77 2 testing (1). However, NP swabbing might expose healthcare workers to the risk of  
78 transmission during sampling and is a relatively invasive method, especially when  
79 considering the multiple samplings a patient will go through during his hospital stay. On the  
80 other hand, there is growing evidence advocating on the role of salivary or oropharyngeal  
81 specimens as alternative non-invasive methods for SARS-CoV-2 diagnosis (2-6).

82 At the same time and as a response to the growing SARS-CoV-2 pandemic and reagents  
83 shortages for rapid molecular systems, multiple rapid point-of-care tests (POCTs) have been  
84 added to the diagnostic pipeline for COVID-19 (7, 8).

85 Little is known on the utility and diagnostic performances of the above-mentioned strategies  
86 in moderately to severely ill hospitalized patients. Current literature shows discordant  
87 results, depending on the clinical setting studied, the sampling method or even the use or  
88 not of a viral transport medium (VTM) (2-6, 9-17).

89 In order to simultaneously investigate analytical [RT-PCR versus Rapid Antigen Test (RAT)]  
90 and sampling procedures (NP swab versus saliva specimen and use versus not of VTM) we  
91 conducted a prospective observational study in hospitalized patients. Our aim was to:

- 92 1) compare the diagnostic performances of NP RT-PCR and salivary RT-PCR,
- 93 2) evaluate the reliability of RAT in hospitalized patients,
- 94 3) compare the sensitivity of RATs performed on NP swab versus saliva in this specific  
95 population,

96 4) evaluate the impact of VTM on the diagnostic performance of RAT.

97

## 98 **Methods**

99

### 100 ***Study population***

101 We conducted a prospective observational study among SARS-CoV-2 positive patients  
102 hospitalized in our institution, a tertiary university hospital in Lausanne, Switzerland (CHUV),  
103 between December 10, 2020 and February 1, 2021. All patients were previously COVID-19  
104 confirmed cases (via NP RT-PCR) and hospitalized either in internal medicine ward, or in  
105 intensive care unit (ICU). Inclusion criteria were a) positive NP RT-PCR for SARS-CoV-2 in the  
106 previous 5 days, b) age >18 years-old and c) informed consent acquisition by the patient or  
107 the next of a kin for patients incapable to provide informed consent. We collected no  
108 additional personal or clinical data beyond the usual information required for every SARS-  
109 CoV-2 test by the Federal Office of Public Health (FOPH) and our microbiology laboratory  
110 (age, sex, hospitalization ward, type and duration of symptoms).

111

### 112 ***Sample Collection and Diagnostic tests***

113 After informed consent acquisition, patients underwent two NP swabs [one diluted in  
114 universal VTM (UTM<sup>®</sup> Copan Diagnostics) (“Wet” approach) (17) and one non-diluted (“Dry  
115 approach”)] and a saliva sample also diluted in the same VTM. Paired diluted NP and saliva  
116 samples were analyzed by RT-PCR (Cobas 6800<sup>®</sup>, Roche-Switzerland) (18) and by two rapid  
117 antigen tests (RAT): One Step Immunoassay Exdia COVID-19 Ag (Precision Biosensor, Korea)  
118 and Standard Q<sup>®</sup> COVID-19 Rapid Antigen Test (Roche-Switzerland). The non-diluted NP swab  
119 was tested with Standard Q<sup>®</sup> COVID-19 Rapid Antigen Test (Roche – Switzerland) at patient’s

120 bedside in order to evaluate the effect of VTM on diagnostic performances of RAT. Both  
121 “Wet” and “Dry” approaches are recommended by the manufacturers of both RAT used. An  
122 additional manipulation step using VTM tubes was performed for an in vitro evaluation of a  
123 possible dilution effect of VTM (see section “*In vitro testing of dilution effect*” below).  
124 All samples were taken by two specialists in infectious diseases (AK and GC) or a member of  
125 a paramedic team trained in NP swabs collection (coming from a team performing all COVID-  
126 19 samples in our hospital). NP was performed according to the recent CDC and WHO  
127 guidelines (19, 20) and saliva sampling protocol was based on previously published data  
128 adapted for hospitalized patients (**supplementary material, S1**) (5). Each nasopharyngeal  
129 swab was performed on a different naris, which was randomly chosen for each sample.

130

### 131 ***Quantitative SARS-CoV-2 PCR and RAT***

132 RT-PCR was performed in our microbiology laboratory using the automated Cobas 6800®  
133 system (Roche-Switzerland) (18). In order to quantify the viral load (VL) based on the  
134 number of cycles threshold (Ct) obtained with the molecular platform, we used the following  
135 equation, derived from RNA quantification:  $VL = (10^{((Ct - 40.856) / -3.697)}) * 100$ . Details on  
136 methods used to derive this equation were described elsewhere (21). The analytical limit of  
137 detection was determined to be at 1000 copies per ml. For graphical representation  
138 purposes, NP or salivary samples with undetectable VL are represented in graphs with VL  
139 determined to be at 500 copies/ml.

140 NP swabs and saliva samples were used to assess RAT performances. NP swabs were either  
141 directly suspended in the buffer solution (“Dry approach”), or initially suspended in 3 ml of  
142 VTM (“Wet” approach). One hundred and fifty µl of the sample were subsequently mixed  
143 with the buffer solution. Saliva samples were only treated with the “Wet” approach. Reading

144 of the results was performed after 15 to 30 minutes as specified by manufacturer's  
145 instructions (on a band of immunochromatography paper for Standard Q<sup>®</sup> COVID-19 Rapid  
146 Antigen Test or using Exdia TRF Biosensor to detect immunofluorescence signal for One Step  
147 Immunoassay Exdia COVID-19 Ag). In case of doubtful results, the Standard Q<sup>®</sup> COVID-19  
148 Rapid Antigen Test test was read independently by a second person.

149

### 150 ***In vitro testing of dilution effect***

151 In order to test *in vitro* a possible dilution effect generated by the use of VTM tubes instead  
152 of direct testing, we simulated the two sampling scenarios: the “Wet” scenario versus the  
153 “Dry” swab scenario (**supplementary material, S2\_Figure 1**). A SARS-CoV-2 positive clinical  
154 NP sample was diluted 7 times and the series was used as internal reference for the limit of  
155 detection. Each initial sample of this dilution series represented a “Dry” swab. Then, two  
156 clean swabs were soaked in each one of the dry samples and then suspended in two further  
157 VTM tubes, thus simulating two series of “Wet” samples. Each sample from every series was  
158 tested as follows:

- 159 i) One Step Immunoassay Exdia COVID-19 Ag (Precision Biosensor, Korea) and Standard  
160 Q<sup>®</sup> COVID-19 Rapid Antigen Test (Roche-Switzerland) were performed after mixing  
161 350 µl of VTM with the buffer solution provided in the RAT kit;
- 162 ii) a clean swab was first inoculated in the VTM, then mixed with the buffer solution  
163 (according to manufacturer instructions) and tested with the previously mentioned  
164 commercial kits and
- 165 iii) 300 µl of VTM were used for RT-PCR analysis.

166

### 167 ***Statistical analysis***

168 Descriptive statistics were presented as number and percentage for categorical variables and  
169 mean  $\pm$  standard deviation (SD) or median (interquartile range; IQR) for continuous  
170 variables. Chi-square or Fisher's exact test were used for categorical variables and Wilcoxon  
171 matched-pairs rank test for continuous variables where appropriate. Sensitivity, specificity,  
172 positive and negative predictive values and 95% CI were calculated to assess diagnostic  
173 performances using a positive NP or saliva RT-PCR as reference standard. All statistical  
174 analyses were performed using GraphPad Prism version 8.3.0 for Windows (GraphPad  
175 Software, San Diego, California USA).

176

### 177 ***Ethics***

178 This project was conducted in accordance with the Declaration of Helsinki, the principles of  
179 Good Clinical Practice and the Swiss Human Research Act (HRO). The project received  
180 approval from the Ethics Committee of canton Vaud, Switzerland (2020–02818). The study  
181 was registered on ClinicalTrials.gov with the number NCT04839094.

182

183

184

### 185 **Results**

186

#### 187 ***Patients' characteristics***

188 All patients with confirmed SARS-CoV-2 infection by NP RT-PCR and admitted in ICU or  
189 Internal Medicine ward during the study period were screened for eligibility criteria. **Figure 1**  
190 shows the flowchart of the screening process. A total of 58 paired NP and saliva samples  
191 were performed with a positivity rate of 85% (time elapsed from screening sample to



192 inclusion could be up to 5 days). Baseline demographics and clinical characteristics are  
193 shown on **Table 1**. Patients were predominantly males (n=45, 77%) with a median age of 70  
194 years-old (IQR 61-77). Most of them still had symptoms upon sampling (n=49, 84%) with a  
195 median duration of symptoms of 11 days (IQR, 5-19). Common symptoms on presentation  
196 were dyspnea (n=27, 46%), cough (n=19, 33%) and fever (n=10, 17%). SARS-CoV-2 VL in NP  
197 swab ranged from 3.800 to 9.900.000 copies/ml (median value 48.000 copies/ml).

198

### 199 ***Diagnostic performance of RT-PCR (NP versus saliva) and rapid antigen testing***

200 The diagnostic performance of RT-PCR and RAT for diagnosis of SARS-CoV-2 infection is  
201 shown on **Table 2**. A positive NP RT-PCR or salivary RT-PCR was selected as the reference  
202 standard comparator.

203 NP and salivary RT-PCR exhibited an overall sensitivity of 98% and 69% respectively whereas  
204 the specificity of both assays was of 100%. Noteworthy, the sensitivity of salivary PCR  
205 increased to 81 % (95% CI: 59-88) in patients presented with a duration of symptoms of less  
206 than 10 days. VL (copies/ml) in NP swabs was significantly higher than that detected on  
207 salivary specimens for up to 20 days after illness onset (**Figure 2**). Median VL value in  
208 positive NP swabs with negative paired saliva specimens was 3700 copies/ml (IQR, 2900-  
209 9675). Median duration of illness for those patients was 15 days (IQR, 9-21). ICU patients  
210 had higher VL compared to patients hospitalized in internal medicine ward. Pair testing  
211 results are shown in **Figure 3**. An analysis of the agreement between the two specimens (NP  
212 versus saliva) revealed a fair agreement with a kappa coefficient of 0.37 (95% CI 0.16-0.59;  
213 p=0.001) and an overall proportion of agreement of 72% (proportion of positive agreement  
214 80% and proportion of negative agreement 53%) (**supplementary material, S3\_Figure 2**).

215 RAT exhibited much lower diagnostic performances with sensitivities of 41% and 35% for the  
216 Exdia<sup>®</sup> and Standard Q<sup>®</sup> assays, respectively among hospitalized patients when a wet-swab  
217 approach was used (**Table 2**). Interestingly, the sensitivity of the dry-swab approach was  
218 slightly better [sensitivity 47% (95% CI: 35-62) for Standard Q<sup>®</sup> assay]. These antigen tests  
219 exhibited very low sensitivity of 8% and 4% for Exdia<sup>®</sup> and Standard Q<sup>®</sup> assays, respectively,  
220 when applied to salivary swabs. **Figure 4** shows RAT results according to illness duration and  
221 VL. All RAT performed better in high VL or early in the course of the disease (especially if VL  
222 >10<sup>6</sup> copies/ml and illness duration < 10 days) (**supplementary material, S4\_Figure 3**).

223

#### 224 *In vitro dilution effect*

225 The limit of detection for Standard Q<sup>®</sup> COVID-19 Rapid Antigen Test (Roche-Switzerland)  
226 varied between 25 and 27.4 Ct in the dry and wet procedures, respectively, while for Exdia<sup>®</sup>  
227 it varied between 22.2 and 24.7 Ct, respectively, considering the gene E detected by Cobas  
228 6800<sup>®</sup> (**supplementary material, S5\_Table 1**). Quantification of the VL showed lower Ct  
229 values (between 2 and 5 Ct corresponding to a difference of 1-2 logs) for the dry series  
230 compared to the respective wet series. Ct results from the E or the RdRP gene were  
231 comparable, demonstrating a limited intra-method variability.

232

#### 233 **Discussion**

234

235 The present study sought to evaluate the role of alternative and non-invasive methods for  
236 diagnosis of SARS-CoV-2 infection in moderately and critically ill-hospitalized patients.  
237 Moreover, to our knowledge this is the first study to evaluate the impact of VTM on RAT  
238 results for SARS-CoV-2 diagnosis.

239 Saliva sampling is a promising alternative to NP swabs for SARS-CoV-2 diagnosis, given the  
240 ease of collection and comfort for repetitive testing as well as highly reliable results (2-6, 9-  
241 12). Nonetheless, only few studies evaluated the diagnostic performance of saliva as  
242 compared to NP swab in hospitalized patients (3, 11-13), with results being conflicting. Our  
243 study evaluated hospitalized patients with moderate to very severe disease. Most of them  
244 were still symptomatic upon sampling (84%) and had a wide distribution of VL, ranging from  
245  $10^3$  to  $10^9$  copies/ml. Overall, NP RT-PCR was more sensitive in diagnosis of SARS-CoV-2  
246 infection than RT-PCR performed in saliva sample. VL detected in NP swab was higher (1-2  
247 log copies/ml) than in saliva specimens. It is noteworthy however, that sensitivity of salivary  
248 RT-PCR increased considerably (from 69% to 81%) when considering patients presenting  
249 early in the course of the disease (<10 days). Progressive decrease in VL over time (14) might  
250 explain loss of sensitivity of the salivary RT-PCR, which is more pronounced when testing  
251 patients with more than 10 days of symptoms. In fact, patients in our study with a positive  
252 NP swab and negative saliva sample had low VL (median value of 3700 copies/ml) and a  
253 median duration of symptoms of 15 days. This raises the question of the infectivity of those  
254 patients and suggest that patients not detected by salivary RT-PCR are those who have low  
255 infectivity potential and are late presenters in the course of the disease. Therefore, the  
256 results of our study, along with previous published data (3, 9, 11-13), suggest that saliva  
257 specimens could be a fair non-invasive alternative to NP swabs (if NP swab is contraindicated  
258 for example), especially for those presenting early in the course of illness.

259 A second goal of our study was to evaluate the diagnostic performance of RAT among  
260 hospitalized patients. RAT exhibited unacceptable overall diagnostic performances for  
261 hospitalized patients whether performed in NP swab or in saliva specimens. To date, both  
262 the Federal Office of Public health in Switzerland and the Swiss Society of Microbiology

263 recommend RAT only within the first 4 days of symptoms (22). Nevertheless, very few (if at  
264 all) of hospitalized patients present within this timeframe since the onset of symptoms.  
265 When we tested the diagnostic performance of RAT for patients presenting with less than 10  
266 days of illness, sensitivity remained very low. RAT yielded high diagnostic performances only  
267 for patients with high VL ( $\geq 10^6$  copies/ml) (**supplementary material, S4\_Figure 3**). The much  
268 lower diagnostic performances of RAT in saliva might be explained by the lower VL in saliva  
269 as compared to NP swabs or eventually the presence of mucosal secretory immunoglobulins  
270 targeting SARS-CoV-2 antigens and thus competing with RAT for the same target (14, 23).  
271 Finally, our study evaluated the role of VTM in SARS-CoV-2 diagnosis by RAT. While both  
272 “Wet” and “Dry” procedures are recommended by the manufacturer, previous data suggest  
273 that VTM can influence diagnostic performances of RT-PCR and RAT for SARS-CoV-2  
274 detection (15, 24). This is the first study to our knowledge that evaluates “head to head” a  
275 “Wet” versus “Dry” RAT procedure for SARS-CoV-2 detection. Our *in vitro* evaluation showed  
276 higher Ct levels for the “Wet” series of both antigen tests used, suggesting a dilution effect  
277 when the swab is immersed in the VTM. Our “head to head” clinical comparison confirmed  
278 the *in vitro* experimentation, showing that the “Dry” NP swab performed slightly better than  
279 the “Wet” one (sensitivity increasing from 35% to 47%), likely due to a decreased dilution of  
280 the sample. While RAT can not be recommended for hospitalized patients, the observed  
281 difference between “Wet” and “Dry” swabs should be taken into account when performing  
282 RAT for SARS-CoV-2 diagnosis in an outpatient setting. Still, when RAT are just used as a  
283 supplementary triaging step at the hospital entry to fasten isolation of highly contagious  
284 subjects, the use of a wet swab approach is also acceptable since the lower sensitivity is  
285 compensated by the fact that in high pandemic period, performing a single sampling for both  
286 RAT and PCR is likely a good and effective option (14).

287 Our study has the strength to test prospectively hospitalized patients with variable disease  
288 severity (ICU versus Internal Medicine ward) and a wide distribution of VL and symptoms  
289 duration. This study gives an insight on the diagnostic performances of different tests in real  
290 life conditions in hospitalized patients. Moreover, it is the first study to our knowledge, to  
291 evaluate the impact of VTM on the RAT ability to detect SARS-CoV-2.

292 On the other hand, this study has a few limitations as well. Its monocentric nature and  
293 limited sample size require our results to be confirmed by larger prospective trials. Our  
294 patients were initially diagnosed with NP swab RT-PCR that might have induced a bias  
295 towards subsequent NP swabs being more often positive versus other samples. Hospitalized  
296 patients may have altered saliva production or composition (25) that could influence saliva  
297 based diagnostic strategies or even explain the differences observed in salivary RT-PCR  
298 performances among severely and mildly ill COVID-19 patients. We chose to use a validated  
299 and easy to use non-invasive saliva collection procedure (5). It is possible that other methods  
300 of saliva collection (such as throat washing for example) would have improved diagnostic  
301 yield and should therefore be tested in other comparative trials.

302 In conclusion, NP swab RT-PCR was the most sensitive method to diagnose SARS-CoV-2  
303 infection in moderately to critically ill hospitalized patients. Salivary RT-PCR could be used as  
304 an alternative non-invasive method if NP swabs are contraindicated, particularly for patients  
305 presenting early in the course of the disease. VTM induced dilution effect can impact  
306 diagnostic performance of RAT.

307

308

309 **Contributions**

310 AK, GC and GG conceived and designed the study, performed the literature research,  
311 analyzed data and performed statistical analyses, drafted and revised the article. AK and GC  
312 collected moreover patient's data and performed hands-on conduct study's diagnostic  
313 procedures. RB conceived and designed the study, provided essential reagents and materials  
314 and performed in vitro experiments. JPM was responsible for project administration in ICU  
315 and collected patient's data. SAM and SG were responsible for project administration in ICU.  
316 OO designed the study and provided essential reagents and materials. AC conceived and  
317 designed the study and provided essential reagents and materials. PV designed the study  
318 and was responsible for the project administration in Internal Medicine Ward. PAB designed  
319 the study and was responsible for the project administration in Internal Medicine Ward. JDC  
320 designed the study and was responsible for the project administration in ICU. All authors  
321 revised the article and approved the submitted version.

322

### 323 **Declarations of interests**

324 The authors have no conflict of interest to disclose.

325

### 326 **Funding**

327 This study was funded by the funds of the Microbiology Institute of Lausanne University  
328 Hospital.

329

### 330 **Ethical Approval**

331 The project received approval from the Ethics Committee of canton Vaud, Switzerland (2020–  
332 02818).

333

## 334 **Acknowledgement**

335 We would like to thank all the technical staff of the Microbiology Institute of Lausanne  
336 University Hospital who performed routine RT-PCRs as well as the entire medical and nurse  
337 team of intensive care unit and internal medicine ward for their precious help in realization of  
338 the project.

339

340

## 341 **References**

342

- 343 1. WHO. Diagnostic testing for SARS-CoV-2 2020 [updated 11.09.2020. Available from:  
344 <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>.
- 345 2. Butler-Laporte G, Lawandi A, Schiller I, Yao M, Dendukuri N, McDonald EG, et al.  
346 Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for  
347 Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med.  
348 2021;181(3):353-60.
- 349 3. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, et al. Sensitivity of  
350 nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome  
351 coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020.
- 352 4. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G,  
353 Suksuwan W, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus  
354 disease 2019: a cross-sectional study. Clin Microbiol Infect. 2021;27(2):285 e1- e4.

- 355 5. Schwob J-M, Miauton A, Petrovic D, Perdrix J, Senn N, Jatton K, et al. Title: Antigen  
356 rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective  
357 comparative clinical trial. medRxiv. 2020.
- 358 6. Large parallel screen of saliva and nasopharyngeal swabs in a test center setting  
359 proves utility of saliva as alternate specimen for SARS-CoV-2 detection by RT-PCR. [Internet].  
360 2020. Available from: <https://www.medrxiv.org/content/10.1101/2020.12.01.20241778v1>.
- 361 7. FIND. SARS-CoV-2 DIAGNOSTIC PIPELINE 2021 [Available from:  
362 [https://www.finddx.org/covid-](https://www.finddx.org/covid-19/pipeline/?avance=all&type=Rapid+diagnostic+tests&test_target=Antigen&status=all&section=show-all&action=default)  
363 [19/pipeline/?avance=all&type=Rapid+diagnostic+tests&test\\_target=Antigen&status=all&sec](https://www.finddx.org/covid-19/pipeline/?avance=all&type=Rapid+diagnostic+tests&test_target=Antigen&status=all&section=show-all&action=default)  
364 [tion=show-all&action=default](https://www.finddx.org/covid-19/pipeline/?avance=all&type=Rapid+diagnostic+tests&test_target=Antigen&status=all&section=show-all&action=default).
- 365 8. Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jatton K, et al. Diagnostic  
366 strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clinical  
367 Microbiology and Infection. 2020;26(9):1178-82.
- 368 9. Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, et al. Saliva is more  
369 sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild  
370 COVID-19 infection. Sci Rep. 2021;11(1):3134.
- 371 10. Skolimowska K, Rayment M, Jones R, Madona P, Moore LSP, Randell P. Non-invasive  
372 saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low  
373 prevalence. Clin Microbiol Infect. 2020;26(12):1711-3.
- 374 11. Berenger BM, Conly JM, Fonseca K, Hu J, Louie T, Schneider AR, et al. Saliva collected  
375 in universal transport media is an effective, simple and high-volume amenable method to  
376 detect SARS-CoV-2. Clin Microbiol Infect. 2020.



- 377 12. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar  
378 P, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J*  
379 *Med.* 2020;383(13):1283-6.
- 380 13. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, et al. Saliva is a  
381 reliable tool to detect SARS-CoV-2. *J Infect.* 2020;81(1):e45-e50.
- 382 14. Caruana G, Croxatto A, Kampouri E, Kritikos A, Opota O, Foerster M, et al.  
383 ImplemeNting SARS-CoV-2 Rapid antigen testing in the Emergency wArd of a Swiss univErsity  
384 hospital: the INCREASE study. *medRxiv.* 2021:2021.02.10.21250915.
- 385 15. Kirkland PD, Frost MJ. The impact of viral transport media on PCR assay results for  
386 the detection of nucleic acid from SARS-CoV-2. *Pathology.* 2020;52(7):811-4.
- 387 16. Rogers AA, Baumann RE, Borillo GA, Kagan RM, Batterman HJ, Galdzicka MM, et al.  
388 Evaluation of Transport Media and Specimen Transport Conditions for the Detection of  
389 SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR. *Journal of Clinical Microbiology.*  
390 2020;58(8):e00708-20.
- 391 17. Walsh P, Overmyer CL, Pham K, Michaelson S, Gofman L, DeSalvia L, et al.  
392 Comparison of respiratory virus detection rates for infants and toddlers by use of flocked  
393 swabs, saline aspirates, and saline aspirates mixed in universal transport medium for room  
394 temperature storage and shipping. *J Clin Microbiol.* 2008;46(7):2374-6.
- 395 18. Opota O, Brouillet R, Greub G, Jaton K. Comparison of SARS-CoV-2 RT-PCR on a high-  
396 throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic  
397 of COVID-19 on various clinical samples. *Pathog Dis.* 2020;78(8).
- 398 19. Prevention. CfDCa. Interim guidelines for collecting, handling, and testing clinical  
399 specimens from persons for coronavirus disease 2019 (COVID-19). Centers for Disease  
400 Control and Prevention; April 14, 2020 [Available from:

401 [https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#additional-resources)  
402 [specimens.html#additional-resources](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#additional-resources).

403 20. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal Swab Specimen. N  
404 Engl J Med. 2020;382(22):e76.

405 21. Jacot D, Greub G, Jatton K, Opota O. Viral load of SARS-CoV-2 across patients and  
406 compared to other respiratory viruses. Microbes Infect. 2020;22(10):617-21.

407 22. Adrian Egli RL, Katia Jatton and Gilbert Greub for the Swiss Society of Microbiology.  
408 Recommendation of the Swiss Society of Microbiology for usage of SARS-CoV-2 specific  
409 antigen tests. PIPETTE – SWISS LABORATORY MEDICINE (NR. 6 | DEZEMBER 2020).

410 23. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the  
411 early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577).

412 24. Weitzel T, Legarraga P, Iruretagoyena M, Pizarro G, Vollrath V, Araos R, et al.  
413 Comparative evaluation of four rapid SARS-CoV-2 antigen detection tests using universal  
414 transport medium. Travel Med Infect Dis. 2021;39:101942.

415 25. Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R. Interventions for  
416 the management of dry mouth: topical therapies. Cochrane Database Syst Rev.  
417 2011(12):CD008934.

418

419

420

421 **Tables**

422

423 **Table 1: Baseline demographics and clinical characteristics of patients**

<b>Characteristics</b>	<b>Internal Medicine Patients (n=26)</b>	<b>ICU patients (n=32)</b>	<b>Overall (n=58)</b>
<b>Age (y), median (IQR)</b>	70 (61-77)	71 (62-78)	70 (61-77)
<b>Male, n (%)</b>	20 (77)	25 (78)	45 (77)
<b>Patients with symptoms upon sampling, n (%)</b>	21 (81)	28 (87)	49 (84)
<b>Duration of symptoms, median (IQR)</b>	11 (5-19)	11 (6-19)	11 (5-19)
<b>Type of symptoms, n (%)</b>			
Fever	5 (19)	5 (16)	10 (17)
Cough	8 (31)	11 (34)	19 (33)
Dyspnea	7 (27)	20 (62)	27 (46)
Fatigue	4 (15)	3 (9)	7 (12)
Anosmia/Dysgeusia	1 (4)	2 (6)	3 (5)
Other	6 (23)	8 (25)	14 (24)
<b>Viral load, median (IQR)</b>	43000 (3700-9100000)	82000 (4500-12000000)	48000 (3800-9900000)

(«Viral load» refers to NP swab viral load and is expressed in copies/ml, y=years, IQR=interquartile range).

425 **Table 2: Overall diagnostic performance metrics of the different diagnostic approaches used.**

426

427

428

429

430

431

432

433

434

435

436

437

438

Diagnostic test		Sensitivity (%) [95% CI]	Specificity (%) [95% CI]	PPV (%) [95% CI]	NPV (%) [95% CI]
Nasopharyngeal RT-PCR		98 [89-100]	100 [66-100]	100 [93-100]	90 [56-98]
Salivary RT-PCR PCR		69 [55-82]	100 [66-100]	100 [90-100]	37.5 [28-48]
Nasopharyngeal rapid antigen test	Exdia® ("Wet")	41 [27-56]	100 [63-100]	100 [83-100]	22 [18-26]
	Roche® ("Wet")	35 [22-50]	100 [66-100]	100 [82-100]	22 [19-26]
	Roche® ("Dry")	47 [35-62]	100 [66-100]	100 [86-100]	26 [21-31]
Salivary rapid antigen test	Exdia® ("Wet")	8 [2-20]	100 [66-100]	100 [51-100]	17 [15-18]
	Roche® ("Wet")	4 [0.5-14]	100 [66-100]	100 [18-100]	16 [15-17]

A positive nasopharyngeal or salivary RT-PCR was used as reference standard. "Wet" and "Dry" rapid antigen tests refer to testing performed after soak of the swab ("Wet") in universal viral transport medium (Copan Italia UTM-RT) or directly to patient's bedside after sampling ("Dry").

439 **Figure legends**

440

441 **Figure 1: Flowchart of screening process.**

442

443

444 **Figure 2: Viral load dynamics of NP RT-PCR versus saliva RT-PCR.**

445 **A.** Kinetics of nasopharyngeal and salivary viral load according to symptoms duration upon sampling. The lines connect the mean values of each  
446 period and the shaded areas indicate the mean standard errors (SEM). The inferior grey shaded area represents the detection limit (1000  
447 copies/ml). Specimens with undetectable viral load are shown within the grey dashed area. **B.** Box and whisker plots comparing viral load  
448 between nasopharyngeal and salivary PCR on different periods since symptom onset. Boxes extend from 25<sup>th</sup> to 75<sup>th</sup> percentiles and whiskers  
449 show 5 and 95 percentiles. The lines in the middle of the boxes are plotted at median values. (Results were compared using Wilcoxon matched-  
450 pairs non parametric test, \*\*\*=  $p < 0.001$ , \*\* =  $p < 0.01$ , ns= non significant).

451

452

453 **Figure 3: Viral load trend in person-matched NP and saliva samples (n=49).**

454 The dotted line and shaded grey area delimit our assay's detection limit. For graphical representation purposes, samples within the  
455 undetectable area are represented with values determined to be at 500 copies/ml. The red and blue horizontal lines represent median values  
456 (\*\*\*\*= $p < 0.0001$  with Wilcoxon signed-rank test).

457

458


459 **Figure 4: Rapid antigen test results according to time since onset of symptoms and viral load.**

460 Full shaded symbols show positive results while no shaded symbols show negative RAT results.


461

462

463



466 **Figure 2**



467


468

469

470


471

472





475 **Figure 4**



476